Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
Business11 hours agoTop brokers name 3 ASX shares to buy next week 25 May 2025
-
General21 hours agoZoe Daniel calls for election recount in Goldstein after final count gives Liberal Party’s Tim Wilson 260-vote lead
-
Noosa News21 hours ago‘Stranded’ Eddie the echidna thought to have swum from Bribie Island’s broken tip
-
Business11 hours agoAre your superannuation fees too high? APRA reveals latest industry medians